|
gptkbp:instanceOf
|
gptkb:drug
gptkb:anticoagulant
|
|
gptkbp:activeIngredient
|
gptkb:heparin
|
|
gptkbp:antidote
|
gptkb:protamine_sulfate
|
|
gptkbp:ATCCode
|
gptkb:B01AB01
|
|
gptkbp:brand
|
gptkb:Heparin_Leo
gptkb:Heparin_Sodium_Injection
gptkb:Hep-Lock
|
|
gptkbp:CASNumber
|
9041-08-1
|
|
gptkbp:contraindication
|
active bleeding
severe thrombocytopenia
|
|
gptkbp:discoveredBy
|
gptkb:Jay_McLean
|
|
gptkbp:discoveredIn
|
1916
|
|
gptkbp:eliminationHalfLife
|
1-2 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
variable (polysaccharide mixture)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Heparin Sodium
|
|
gptkbp:includedIn
|
gptkb:World_Health_Organization's_List_of_Essential_Medicines
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
bleeding
thrombocytopenia
osteoporosis (with long-term use)
|
|
gptkbp:UNII
|
GSL0D8G5X8
|
|
gptkbp:usedFor
|
prevention of blood clots
treatment of deep vein thrombosis
treatment of pulmonary embolism
prevention of clotting in medical devices
|
|
gptkbp:bfsParent
|
gptkb:heparin
gptkb:Heparin
|
|
gptkbp:bfsLayer
|
6
|